Gunderson Dettmer represented client Xencor, a clinical-stage biopharmaceutical company, in its partnership agreement with UCLA’s Technology Development Group to develop new drugs.

In the announcement of the transaction, chief science officer of Xencor John Desjarlais said, “We look forward to collaborating with UCLA’s investigators to translate their biological insights into potential medicines.” Senior director of biopharmaceuticals at UCLA’s Technology Development Group Mark Wisniewski added, “With this collaboration, we aim to accelerate the development of potential new biologic medicines, leveraging Xencor’s protein engineering technologies and expertise and the ongoing scientific discoveries and insights into disease biology made at UCLA, with the ultimate goal to improve patient outcomes and quality of life.”

The Gunderson deal team was led by Brendan McCarthy.